Randy Hall

Randy Hall has had a long career in strategic marketing and program effectiveness within the pharmaceutical, information technology and market research industries. His expertise includes activating patient advocates, professional societies, thought leaders and other third party organizations to meet corporate and brand objectives. He is highly skilled at designing and directing the integration and implementation of advocacy relations, professional relations, thought leader development, multi-cultural marketing and direct to consumer marketing programs. 

Mr. Hall has successfully led new business development, strategic marketing initiatives and constituency and public relations programs that have generated hundreds of millions of dollars in revenues for organizations worldwide, including Eli Lilly and Company, Bristol Myers Squibb, INTELMED, Federal Market Intelligence Systems, Advance Incorporated, American University and The Omega Group.  He has managed business units with as many as 150 employees and $20 million budgets.

Mr. Hall earned a Bachelor of Science degree from The John Hopkins University and completed course work and training at numerous institutions including George Washington University’s Masters in Telecommunications program, Georgetown University Graduate Studies in Legislative Affairs and the University of Pennsylvania Law School. 

Since retiring Mr. Hall assisted several not-for profit organizations to develop strategic marketing plans, improve programmatic effectiveness and increase revenues.  He sits on the board or volunteers for many groups including the Association of Clinicians for the Underserved, the New Jersey Association of Mental Health Agencies, the National Black Nurses Association, the St. Vincent’s Hospital Network, 100 Black Men and Coppin State University. 

Mr. Hall also maintains a small management consulting practice, specializing in providing guidance and support to corporate clients.   Recent projects include developing strategic marketing plans for medicines for infectious diseases and improving marketing program efficiencies for neurological disorders.